<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Geriatr</journal-id><journal-id journal-id-type="iso-abbrev">BMC Geriatr</journal-id><journal-title-group><journal-title>BMC Geriatrics</journal-title></journal-title-group><issn pub-type="epub">1471-2318</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410709</article-id><article-id pub-id-type="pmc">PMC12100790</article-id><article-id pub-id-type="publisher-id">5951</article-id><article-id pub-id-type="doi">10.1186/s12877-025-05951-4</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Evaluation of the utility of different laboratory test-related sarcopenia indices as predictors of lung cancer mortality</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Chen</surname><given-names>Xiaoyan</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Luo</surname><given-names>Shuyue</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Hou</surname><given-names>Lisha</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Yang</surname><given-names>Ming</given-names></name><address><email>yangmier@scu.edu.cn</email><email>yangmier@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Hao</surname><given-names>Qiukui</given-names></name><address><email>haoqiukui@gmail.com</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><aff id="Aff1"><label>1</label>Department of Geriatric, The Zigong Affliated Hospital, SouthwestMedical University, Zigong, Sichuan China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/011ashp19</institution-id><institution-id institution-id-type="GRID">grid.13291.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 0807 1581</institution-id><institution>West China Hospital, </institution><institution>National Clinical Research Center for Geriatrics, Sichuan University, </institution></institution-wrap>Chengdu, Sichuan Province China </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>25</volume><elocation-id>367</elocation-id><history><date date-type="received"><day>29</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Objectives</title><p id="Par1">We evaluated the utility of routine laboratory test-related sarcopenia indices as predictors of mortality in older patients with primary lung cancer undergoing the first chemotherapy course.</p></sec><sec><title>Design</title><p id="Par2">Retrospective cohort study.</p></sec><sec><title>Setting</title><p id="Par3">West China Hospital, Chengdu, China.</p></sec><sec><title>Participants</title><p id="Par4">This study enrolled primary lung cancer patients&#x02009;&#x02265;&#x02009;60 years of age undergoing their first chemotherapy course.</p></sec><sec><title>Measurements</title><p id="Par5">Data on individual patients were obtained from the medical records, while information on survival outcomes was gathered through telephone-based follow-up or local government databases. Using available routine hematological and biochemical test results, this study calculated three sarcopenia-related indices for each patient. These indices included the AST/ALT ratio, neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR). We assessed the relationships between these indices and death using Cox proportional hazards models.</p></sec><sec><title>Results</title><p id="Par6">The study included 926 primary lung cancer patients (71.5% male; median age: 65 years) who underwent their first course of chemotherapy. During the follow-up period (median: 28 months), 563 patients (60.8%) died. In the overall population, there was a significantly higher likelihood of all-cause mortality in patients with an NLR&#x02009;&#x02265;&#x02009;2.88 (HR&#x02009;=&#x02009;1.60, 95% CI&#x02009;=&#x02009;1.36&#x02013;1.90, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) or a PLR&#x02009;&#x02265;&#x02009;125.11 (HR&#x02009;=&#x02009;1.39, 95% CI&#x02009;=&#x02009;1.17&#x02013;1.64, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) compared to those with values below these thresholds. However, after adjustment for potential confounding factors, no association was found between NLR or PLR and mortality. After stratification by sex, it was found that both NLR and PLR values were associated with an increased risk of mortality among women (NLR: HR&#x02009;=&#x02009;2.1, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; PLR: HR&#x02009;=&#x02009;2.42, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001).</p></sec><sec><title>Conclusions</title><p id="Par7">NLR and PLR, are indicators of sarcopenia and can be easily derived from routine laboratory testing data. These indices can significantly predict mortality in older female patients with primary lung cancer at the start of chemotherapy. Therefore, there is potential practical value in using these indices for assessing patient risk prior to chemotherapy.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s12877-025-05951-4.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Sarcopenia index</kwd><kwd>Prognosis</kwd><kwd>Older patients</kwd><kwd>Lung cancer</kwd></kwd-group><funding-group><award-group><funding-source><institution>Zigong Brain Science Research Institute Collaborative Innovation Category</institution></funding-source><award-id>2023-NKY-01-03, 2024-NKY-01-03</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution>Zigong Psychiatric Research Center scientific research project</institution></funding-source><award-id>2022ZD01, 2022ZD03</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par8">Lung cancer remains the most commonly diagnosed malignancy worldwide and a leading cause of cancer-related mortality, particularly among older adults who exhibit a significantly higher risk [<xref ref-type="bibr" rid="CR1">1</xref>]. In many cases, the disease is diagnosed at an intermediate or advanced stage in this group. The increasingly advanced interventional strategies can provide these patients with opportunities for chemotherapy, radiotherapy, and other therapeutic approaches [<xref ref-type="bibr" rid="CR2">2</xref>]. Even with these interventions, however, the overall survival (OS) rates in patients with lung cancer remain limited. This highlights a critical need to identify mortality-related risk factors to facilitate a more tailored and effective management of lung cancer.</p><p id="Par9">Sarcopenia, a clinically important age-related syndrome, is characterized by a progressive decline in physical performance, muscle strength, and skeletal muscle mass [<xref ref-type="bibr" rid="CR3">3</xref>]. Sarcopenia is common among older adults throughout the world and is associated with numerous adverse health outcomes, including an increased risk of falls [<xref ref-type="bibr" rid="CR4">4</xref>], bone fractures [<xref ref-type="bibr" rid="CR4">4</xref>], functional disability [<xref ref-type="bibr" rid="CR5">5</xref>], and mortality [<xref ref-type="bibr" rid="CR6">6</xref>]. Recently, this condition has emerged as a critical area of focus in oncology, as it has been found to be predictive of adverse outcomes and death among cancer patients [<xref ref-type="bibr" rid="CR6">6</xref>]. Specifically, cancer patients undergoing chemotherapy and/or radiotherapy who also suffer from sarcopenia are more likely to have poorer outcomes and higher mortality [<xref ref-type="bibr" rid="CR6">6</xref>].</p><p id="Par10">Regular assessment of sarcopenia status in accordance with established clinical guidelines presents challenges due to the need for specialized analytical strategies such as CT, MRI, BIA, and DEXA. These methods are not only costly but also require a level of expertise that adds to the workload of clinical staff [<xref ref-type="bibr" rid="CR7">7</xref>]. Early diagnosis of individuals with sarcopenia is crucial, as it enables timely intervention that can help prevent its progression potentially leading to functional disability [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par11">For these reasons, researchers have explored simpler alternative indices to evaluate sarcopenia status, such as the AST/ALT ratio [<xref ref-type="bibr" rid="CR9">9</xref>], the neutrophil-to-lymphocyte ratio (NLR) [<xref ref-type="bibr" rid="CR10">10</xref>], and the platelet-to-lymphocyte ratio (PLR) [<xref ref-type="bibr" rid="CR11">11</xref>]. Each of these indices has shown promise in the effective detection of sarcopenia. However, studies examining the correlations between these indices and all-cause mortality in older patients with primary lung cancer undergoing their first chemotherapy course remain limited. This study aimed to investigate the utility of three different sarcopenia indices in predicting all-cause death among older patients with primary lung cancer.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec7"><title>Study design and participants</title><p id="Par12">This single-center retrospective study enrolled patients aged 60 years and over who had pathologically confirmed primary lung cancer of any type. The patients underwent their first course of chemotherapy at West China Hospital, Sichuan University, from January 2010 through December 2017. Patients were excluded if their medical data were missing or they lacked test results from routine hematological or blood biochemistry analyses. Two investigators independently obtained baseline patient characteristics and health-related data through an anonymized electronic medical records system.</p></sec><sec id="Sec8"><title>Ethical oversight</title><p id="Par13">This study was conducted retrospectively using patient medical records. All relevant data were anonymized by the Health Informatics Center, which was responsible for supervising the study protocol. Throughout the research, the investigators ensured that all data remained confidential and that all analyses were conducted according to the Declaration of Helsinki. Given the anonymized and retrospective nature of this study, the requirement for patient consent was waived. The Research Ethics Committee of West China Hospital, Sichuan University, approved this study (No. 2018&#x02013;94).</p></sec><sec id="Sec9"><title>Sarcopenia index analyses</title><p id="Par14">To assess the sarcopenia status of patients at baseline, sarcopenia indices were computed using a standard approach. Specifically, three sarcopenia indices were analyzed, each derivable from routine hematological and blood biochemistry test results: the AST/ALT ratio, the neutrophil-to-lymphocyte ratio (NLR), and the platelet-to-lymphocyte ratio (PLR). These variables were measured using fasting blood samples collected prior to the first round of chemotherapy for enrolled patients. The cut-off values for these indices were established based on previous studies with an AST/ALT threshold of 1.35 [<xref ref-type="bibr" rid="CR12">12</xref>], an NLR threshold of 2.88 [<xref ref-type="bibr" rid="CR10">10</xref>], and a PLR threshold of 125.11 [<xref ref-type="bibr" rid="CR13">13</xref>].</p></sec><sec id="Sec10"><title>All-cause mortality</title><p id="Par15">Mortality-related data for study participants were initially obtained through a review of local government death registries. In cases where these databases lacked the necessary information, telephone interviews were conducted. The collected mortality data included survival status and the date of death, with a cut-off date for data collection set at April 1, 2018. The median follow-up length was 28 months, and OS was measured from the start of treatment to the occurrence of all-cause death or the last follow-up.</p></sec><sec id="Sec11"><title>Covariates</title><p id="Par16">Baseline patient data prior to the initiation of chemotherapy were collected retrospectively, including age, sex, marital status, occupation, health insurance coverage, body mass index (BMI), smoking and drinking status. A variety of tumor-related parameters were also recorded, including histology, clinical stage, and presence of metastasis, along with details regarding the chemotherapy regimens, radiotherapy, and any lung cancer-related surgeries. Patients were categorized based on their smoking history into current smokers, former smokers, and non-smokers, and their total pack-years of cigarette consumption were also assessed. Any adverse reactions experienced by patients during chemotherapy were also recorded.</p></sec><sec id="Sec12"><title>Statistical analysis</title><p id="Par17">We conducted statistical analyses using SPSS v24.0 (IBM Corp., NY, USA). A two-sided <italic>P</italic>-value of less than 0.05 was considered statistically significant. Data are presented as numbers (percentages) or means&#x02009;&#x000b1;&#x02009;standard deviation or median(q25,q75),as appropriate. The Mann-Whitney U, Pearson&#x02019;s chi-square, and Fisher&#x02019;s exact tests were utilized for comparisons between groups. Binary logistic regression was utilized to assess the associations between each sarcopenia index and short-term outcomes. Kaplan-Meier curves with log-rank tests were utilized to assess survival. Cox proportional hazards models were used to evaluate the impacts of the sarcopenia indices on all-cause mortality. Odds ratios (ORs) for logistic regression and hazard ratios(HRs) for Cox models,along with95% confidence intervals (CIs) were calculated using an unadjusted model and a model adjusted for age, sex, smoking history, BMI, tissue type, clinical stage, radiotherapy, chemotherapy regimen, surgery, and metastasis.</p></sec></sec><sec id="Sec3"><title>Results</title><sec id="Sec13"><title>Patient characteristics</title><p id="Par18">Among the 1,263 individuals initially enrolled in this study, 337 were ultimately excluded due to missing medical records or laboratory data. The analysis included the remaining 926 primary lung cancer patients (71.5% male; median age: 65 years) who underwent their first course of chemotherapy. Mortality was found to be significantly higher among males compared to females (66.16% vs. 47.35%, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). Those who did not survive showed higher rates of smoking than survivors. No statistically significant differences were observed between the groups regarding other conditions such as diabetes, hypertension, and coronary heart disease(CHD).</p><p id="Par19">Adenocarcinoma was the most prevalent histological type among the participants (71.0%), followed by squamous cell carcinoma (15.0%) and small cell carcinoma (14.0%). A majority of these individuals received combination chemotherapy treatment. Compared to survivors, metastatic and advanced disease was more prevalent among individuals who had died (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). A greater proportion of lung cancer survivors underwent surgery (69.26%) compared to decedents (30.74%) (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><p id="Par20">Both the NLR (<italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and PLR (<italic>P</italic>&#x02009;=&#x02009;0.005) were significantly higher among deceased individuals relative to survivors; however, this was not the case for the AST/ALT ratios (<italic>P</italic>&#x02009;=&#x02009;0.25). Therefore, the AST/ALT values were excluded from subsequent survival analyses (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Although some patients experienced adverse reactions while undergoing chemotherapeutic treatment, no statistically significant differences were observed in the incidence of these reactions between survivors and non-survivors (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). We also found that there was no significant difference in sarcopenia indicators between the group without adverse reactions after chemotherapy and the group with adverse reactions after chemotherapy (Table&#x000a0;<xref rid="MOESM1" ref-type="media">1S</xref>).</p><p id="Par21">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>According to the general characteristics of the death distribution</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Non-death<break/><italic>n</italic>&#x02009;=&#x02009;363</th><th align="left">Death<break/><italic>n</italic>&#x02009;=&#x02009;563</th><th align="left">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left"><bold>Age (years)</bold>,<bold> median(p25, p75)</bold></td><td align="left">64(62, 69)</td><td align="left">65(62, 69)</td><td char="." align="char">
<bold>0.048</bold>
</td></tr><tr><td align="left"><bold>Sex</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="left">male</td><td align="left">224(33.84)</td><td align="left">438(66.16)</td><td align="left"/></tr><tr><td align="left">female</td><td align="left">139(52.65)</td><td align="left">125(47.35)</td><td align="left"/></tr><tr><td align="left"><bold>Smoking history</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="left">no</td><td align="left">175(48.88)</td><td align="left">183(51.12)</td><td align="left"/></tr><tr><td align="left">former smoker</td><td align="left">108(38.99)</td><td align="left">169(61.01)</td><td align="left"/></tr><tr><td align="left">current smoker</td><td align="left">80(27.49)</td><td align="left">211(72.51)</td><td align="left"/></tr><tr><td align="left"><bold>Hypertension</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">0.07</td></tr><tr><td align="left">no</td><td align="left">264(37.55)</td><td align="left">439(62.45)</td><td align="left"/></tr><tr><td align="left">yes</td><td align="left">96(44.44)</td><td align="left">120(55.56)</td><td align="left"/></tr><tr><td align="left"><bold>CHD</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">0.394</td></tr><tr><td align="left">no</td><td align="left">349(38.95)</td><td align="left">547(61.05)</td><td align="left"/></tr><tr><td align="left">yes</td><td align="left">14(46.67)</td><td align="left">16(53.33)</td><td align="left"/></tr><tr><td align="left"><bold>COPD</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">0.131</td></tr><tr><td align="left">no</td><td align="left">318(40.2)</td><td align="left">473(59.8)</td><td align="left"/></tr><tr><td align="left">yes</td><td align="left">45(33.33)</td><td align="left">90(66.67)</td><td align="left"/></tr><tr><td align="left"><bold>Diabetes</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">0.473</td></tr><tr><td align="left">no</td><td align="left">314(38.77)</td><td align="left">496(61.23)</td><td align="left"/></tr><tr><td align="left">yes</td><td align="left">49(42.24)</td><td align="left">67(57.76)</td><td align="left"/></tr><tr><td align="left"><bold>Tissue type</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="left">adenocarcinoma</td><td align="left">288(43.84)</td><td align="left">369(56.16)</td><td align="left"/></tr><tr><td align="left">squamous cell carcinoma</td><td align="left">46(33.09)</td><td align="left">93(66.91)</td><td align="left"/></tr><tr><td align="left">small cell carcinoma</td><td align="left">29(22.31)</td><td align="left">101(77.69)</td><td align="left"/></tr><tr><td align="left"><bold>Clinical stage</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="left">I-II</td><td align="left">114(80.28)</td><td align="left">28(19.72)</td><td align="left"/></tr><tr><td align="left">III-IV</td><td align="left">249(31.76)</td><td align="left">535(68.24)</td><td align="left"/></tr><tr><td align="left"><bold>Regimen of Chemotherapy</bold>,<bold> n (%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">
<bold>0.01</bold>
</td></tr><tr><td align="left">
<bold>single</bold>
</td><td align="left">21(25.93)</td><td align="left">60(74.07)</td><td align="left"/></tr><tr><td align="left">
<bold>combination</bold>
</td><td align="left">342(40.47)</td><td align="left">503(59.53)</td><td align="left"/></tr><tr><td align="left"><bold>Radiation therapy</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="left">no</td><td align="left">291(44.84)</td><td align="left">358(55.16)</td><td align="left"/></tr><tr><td align="left">yes</td><td align="left">72(25.99)</td><td align="left">205(74.01)</td><td align="left"/></tr><tr><td align="left"><bold>Metastasis</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="left">no</td><td align="left">97(80.17)</td><td align="left">24(19.83)</td><td align="left"/></tr><tr><td align="left">yes</td><td align="left">266(33.08)</td><td align="left">538(66.92)</td><td align="left"/></tr><tr><td align="left">
<bold>Surgery</bold>
</td><td align="left"/><td align="left"/><td char="." align="char">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="left">no</td><td align="left">176(26.87)</td><td align="left">479(73.13)</td><td align="left"/></tr><tr><td align="left">yes</td><td align="left">187(69.26)</td><td align="left">83(30.74)</td><td align="left"/></tr><tr><td align="left"><bold>BMI</bold>,<bold> kg/m</bold><sup><bold>2</bold></sup>, <bold>mean(SD)</bold></td><td align="left">22.89(2.7)</td><td align="left">22.45(3.21)</td><td char="." align="char">
<bold>0.029</bold>
</td></tr><tr><td align="left">
<bold>ALB level, g/l</bold>
</td><td align="left">40.8(38.3, 42.8)</td><td align="left">38.7(35.6, 41.5)</td><td char="." align="char">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="left"><bold>AST/ALT</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">0.25</td></tr><tr><td align="left">&#x0003c;1.35</td><td align="left">263(40.4)</td><td align="left">388(59.6)</td><td align="left"/></tr><tr><td align="left">&#x02265;&#x02009;1.35</td><td align="left">100(36.36)</td><td align="left">175(63.64)</td><td align="left"/></tr><tr><td align="left"><bold>NLR</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">
<bold>&#x0003c;0.001</bold>
</td></tr><tr><td align="left">&#x0003c;2.88</td><td align="left">211(48.06)</td><td align="left">228(51.94)</td><td align="left"/></tr><tr><td align="left">&#x02265;&#x02009;2.88</td><td align="left">152(31.21)</td><td align="left">335(68.79)</td><td align="left"/></tr><tr><td align="left"><bold>PLR</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">
<bold>0.005</bold>
</td></tr><tr><td align="left">&#x0003c;125.11</td><td align="left">179(44.31)</td><td align="left">225(55.69)</td><td align="left"/></tr><tr><td align="left">&#x02265;&#x02009;125.11</td><td align="left">184(35.25)</td><td align="left">338(64.75)</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Note: CHD, Coronary heart disease;</p><p>COPD, Chronic obstructive pulmonary disease;</p><p>BMI, Body mass index;</p><p>ALB, Albumin;</p><p>AST/ALT,,aspartate aminotransferase to alanine aminotransferase ratio;</p><p>NLR, neutrophil&#x02013;lymphocyte ratio;</p><p>PLR, platelet&#x02013;lymphocyte ratio;</p></table-wrap-foot></table-wrap>
</p><p id="Par22">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Relationship between adverse reactions and mortality</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Non-death<break/><italic>n</italic>&#x02009;=&#x02009;363</th><th align="left">Death<break/><italic>n</italic>&#x02009;=&#x02009;563</th><th align="left">&#x003c7;2/T/Z</th><th align="left">
<italic>P</italic>
</th></tr></thead><tbody><tr><td align="left"><bold>Bone marrow suppression</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">1.186</td><td char="." align="char">0.276</td></tr><tr><td align="left">no</td><td align="left">303(40.03)</td><td align="left">454(59.97)</td><td align="left"/><td align="left"/></tr><tr><td align="left">yes</td><td align="left">60(35.5)</td><td align="left">109(64.5)</td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Digestive reactions</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">1.498</td><td char="." align="char">0.221</td></tr><tr><td align="left">no</td><td align="left">338(38.72)</td><td align="left">535(61.28)</td><td align="left"/><td align="left"/></tr><tr><td align="left">yes</td><td align="left">25(47.17)</td><td align="left">28(52.83)</td><td align="left"/><td align="left"/></tr><tr><td align="left"><bold>Liver function impairment</bold>,<bold> n(%)</bold></td><td align="left"/><td align="left"/><td char="." align="char">0.597</td><td char="." align="char">0.44</td></tr><tr><td align="left">no</td><td align="left">335(38.86)</td><td align="left">527(61.14)</td><td align="left"/><td align="left"/></tr><tr><td align="left">yes</td><td align="left">28(43.75)</td><td align="left">36(56.25)</td><td align="left"/><td align="left"/></tr><tr><td align="left">
<bold>All infection</bold>
</td><td align="left"/><td align="left"/><td char="." align="char">1.775</td><td char="." align="char">0.183</td></tr><tr><td align="left">no</td><td align="left">339(39.84)</td><td align="left">512(60.16)</td><td align="left"/><td align="left"/></tr><tr><td align="left">yes</td><td align="left">24(32)</td><td align="left">51(68)</td><td align="left"/><td align="left"/></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec14"><title>Evaluation of survival status following chemotherapy based on patient sarcopenia indices</title><p id="Par23">Of the 926 patients analyzed, 563 died during the follow-up period. Among those who died, 335 (68.79%) had an NLR of 2.88 or greater, and 338 (64.75%) had a PLR of 125.11 or greater. Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref> shows the survival curves for the overall cohort and for males and females stratified by the NLR and PLR thresholds. An NLR&#x02009;&#x02265;&#x02009;2.88 was associated with significantly poorer survival in the overall cohort and in both sexes (log-rank <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). While males did not show significantly different survival based on PLR&#x02009;&#x02265;&#x02009;125.11(<italic>P</italic>&#x02009;=&#x02009;0.054), both the overall cohort and the female group showed significantly worse survival with PLR&#x02009;&#x02265;&#x02009;125.11 (log-rank <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001).</p><p id="Par24">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Survival curves with primary lung cancer receiving chemotherapy according to baseline sarcopenia index. Note(years): <bold>A</bold>, NLR(toal); OS(4.527 vs. 3.087);blue, NLR&#x0003c;2.88, green, NLR&#x02009;&#x02265;&#x02009;2.88; <bold>B</bold>, PLR(toal); OS(4.65 vs.3.302);blue, PLR&#x0003c;125.11, green, PLR&#x02009;&#x02265;&#x02009;125.11; <bold>C</bold>, NLR(male); OS(3.541 vs.2.958);blue, NLR&#x0003c;2.88, green, NLR&#x02009;&#x02265;&#x02009;2.88; <bold>D</bold>, PLR(male); OS(3.416 vs. 3.038);blue, PLR&#x0003c;125.11, green, PLR&#x02009;&#x02265;&#x02009;125.11; <bold>E</bold>, NLR(female); OS(4.527 vs.3.087);blue, NLR&#x0003c;2.88, green, NLR&#x02009;&#x02265;&#x02009;2.88; <bold>F</bold>, PLR(female); OS(4.65 vs. 3.302);blue, PLR&#x0003c;125.11, green, PLR&#x02009;&#x02265;&#x02009;125.11;</p></caption><graphic xlink:href="12877_2025_5951_Fig1_HTML" id="d33e1179"/></fig>
</p><p id="Par25">In the unadjusted analysis, both an NLR of 2.88 or greater (HR&#x02009;=&#x02009;1.60, 95% CI&#x02009;=&#x02009;1.36&#x02013;1.90, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) and a PLR of 125.11 or greater (HR&#x02009;=&#x02009;1.39, 95% CI&#x02009;=&#x02009;1.17&#x02013;1.64, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001) were significantly associated with an increased risk of all-cause mortality. However, after adjusting for age, sex, smoking history, BMI, tissue type, clinical stage, chemotherapy regimen, radiotherapy, metastasis, surgery, and ALB level, the association between NLR or PLR and OS was not significant (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par26">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Association between sarcopenia index and mortality</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="2">Sarcopenia index</th><th align="left" colspan="2">Unadjusted</th><th align="left" colspan="2">Adjusted</th></tr><tr><th align="left"><italic>P</italic>-value</th><th align="left">HR (95% CI)</th><th align="left"><italic>P</italic>-value</th><th align="left">HR (95% CI)</th></tr><tr><th align="left" colspan="6">
<bold>Total</bold>
</th></tr></thead><tbody><tr><td align="left"/><td align="left">
<bold>NLR</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"/><td align="left">&#x0003c;2.88</td><td align="left">-</td><td align="left">1</td><td align="left">-</td><td align="left">1</td></tr><tr><td align="left"/><td align="left">&#x02265;&#x02009;2.88</td><td align="left">
<bold>&#x0003c;0.001</bold>
</td><td align="left">1.60(1.36&#x02013;1.9)</td><td align="left">0.932</td><td align="left">1.01(0.84&#x02013;1.21)</td></tr><tr><td align="left"/><td align="left">
<bold>PLR</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"/><td align="left">&#x0003c;125.11</td><td align="left">-</td><td align="left">1</td><td align="left">-</td><td align="left">1</td></tr><tr><td align="left"/><td align="left">&#x02265;&#x02009;125.11</td><td align="left">
<bold>&#x0003c;0.001</bold>
</td><td align="left">1.39(1.17&#x02013;1.64)</td><td align="left">0.348</td><td align="left">0.92(0.76&#x02013;1.1)</td></tr><tr><td align="left">
<bold>Male</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"/><td align="left">
<bold>NLR</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"/><td align="left">&#x0003c;2.88</td><td align="left">-</td><td align="left">1</td><td align="left">-</td><td align="left">1</td></tr><tr><td align="left"/><td align="left">&#x02265;&#x02009;2.88</td><td align="left">
<bold>0.004</bold>
</td><td align="left">1.33(1.1&#x02013;1.61)</td><td align="left">0.133</td><td align="left">0.85(0.69&#x02013;1.05)</td></tr><tr><td align="left"/><td align="left">
<bold>PLR</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"/><td align="left">&#x0003c;125.11</td><td align="left">-</td><td align="left">1</td><td align="left">-</td><td align="left">1</td></tr><tr><td align="left"/><td align="left">&#x02265;&#x02009;125.11</td><td align="left">0.054</td><td align="left">1.21(1-1.46)</td><td align="left">0.416</td><td align="left">1.09(0.89&#x02013;1.34)</td></tr><tr><td align="left">
<bold>Female</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"/><td align="left">
<bold>NLR</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"/><td align="left">&#x0003c;2.88</td><td align="left">-</td><td align="left">1</td><td align="left">-</td><td align="left">1</td></tr><tr><td align="left"/><td align="left">&#x02265;&#x02009;2.88</td><td align="left">
<bold>&#x0003c;0.001</bold>
</td><td align="left">2.52(1.86&#x02013;3.61)</td><td align="left">
<bold>&#x0003c;0.001</bold>
</td><td align="left">2.1(1.42&#x02013;3.09)</td></tr><tr><td align="left"/><td align="left">
<bold>PLR</bold>
</td><td align="left"/><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"/><td align="left">&#x0003c;125.11</td><td align="left">-</td><td align="left">1</td><td align="left">-</td><td align="left">1</td></tr><tr><td align="left"/><td align="left">&#x02265;&#x02009;125.11</td><td align="left">
<bold>&#x0003c;0.001</bold>
</td><td align="left">2.29(1.57&#x02013;3.34)</td><td align="left">
<bold>&#x0003c;0.001</bold>
</td><td align="left">2.42(1.59&#x02013;3.68)</td></tr></tbody></table><table-wrap-foot><p>Note:</p><p>Model 1, Unadjusted model;</p><p>Model2, Adjusted for age, sex, smoking history, tissue type, clinical stage, regimen of chemotherapy, radiation therapy, metastasis, surgery, BMI, ALB level</p></table-wrap-foot></table-wrap>
</p><p id="Par27">In males, an NLR&#x02009;&#x02265;&#x02009;2.88 was significantly associated with poor OS in the unadjusted model (HR&#x02009;=&#x02009;1.33, 95% CI&#x02009;=&#x02009;1.1&#x02013;1.61, <italic>P</italic>&#x02009;=&#x02009;0.004); however, this association was not statistically significant after adjustment for the above potential confounding factors (HR&#x02009;=&#x02009;0.85, 95% CI&#x02009;=&#x02009;0.69&#x02013;1.05, <italic>P</italic>&#x02009;=&#x02009;0.133). In males, there was also no significant association between PLR&#x02009;&#x02265;&#x02009;125.11 and OS (non-adjusted model: HR&#x02009;=&#x02009;1.21, 95% CI&#x02009;=&#x02009;1-1.46, <italic>P</italic>&#x02009;=&#x02009;0.054; adjusted model: HR&#x02009;=&#x02009;1.09, 95% CI&#x02009;=&#x02009;0.89&#x02013;1.34, <italic>P</italic>&#x02009;=&#x02009;0.416; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par28">In females, both an NLR&#x02009;&#x02265;&#x02009;2.88 and a PLR&#x02009;&#x02265;&#x02009;125.11 were significantly associated with poor OS, even after adjustment for potential confounding variables (NLR: HR [non-adjusted model]&#x02009;=&#x02009;2.52, 95% CI&#x02009;=&#x02009;1.86&#x02013;3.61, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; HR [adjusted model]&#x02009;=&#x02009;2.1, 95% CI&#x02009;=&#x02009;1.42&#x02013;3.09, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; PLR: HR [non-adjusted model]&#x02009;=&#x02009;2.29, 95% CI&#x02009;=&#x02009;1.57&#x02013;3.34, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; HR [adjusted model]&#x02009;=&#x02009;2.42, 95% CI&#x02009;=&#x02009;1.59&#x02013;3.68, <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001; Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).</p></sec></sec><sec id="Sec4"><title>Discussion</title><p id="Par29">This study investigated the predictive value of sarcopenia indices, specifically, the NLR and PLR, for all-cause mortality in 926 patients aged 60 and over with primary lung cancer undergoing their first cycle of chemotherapy. It was found that both NLR and PLR were associated with OS, suggesting their potential as accessible risk-assessing tools for older patients with lung cancer in clinical practice. Laboratory-based indicators (such as NLR and PLR) require only routine blood tests, eliminating the need for additional imaging analyses or specialized equipment. This makes them particularly advantageous in resource-limited settings, healthcare institutions where CT scans are not readily available, or for community populations and patients. Furthermore, for patients who have already undergone CT scans, laboratory indicators can be used in conjunction with imaging metrics to provide a more comprehensive dynamic follow-up assessment of prognosis.</p><p id="Par30">While previous studies have observed an association between NLR values and all-cause mortality in patients with non-small cell lung cancer [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>], we observed this association only in female patients. PLR, similarly, was associated with increased mortality risk in this female subgroup. The potential reasons for the differences between males and females may include the following: (1) Biological mechanisms underlying sex differences, as there are significant differences in hormone levels (such as estrogen and androgen) between males and females. Estrogen has anti-inflammatory effects, which may enhance female sensitivity to inflammatory markers (such as NLR and PLR). In contrast, male sex may be associated with weaker NLR and PLR predictive ability due to the lack of estrogen [<xref ref-type="bibr" rid="CR16">16</xref>]. (2) Sex differences in immune responses: studies have shown that females generally have more active immune systems compared to males, indicating that inflammatory markers may be more reflective of disease status or prognosis in women [<xref ref-type="bibr" rid="CR17">17</xref>]. (3) For chemotherapy tolerance, studies indicate that females may experience higher toxicity rates and different therapeutic outcomes compared to males in lung cancer [<xref ref-type="bibr" rid="CR18">18</xref>].</p><p id="Par31">Several biological mechanisms may explain the association between NLR or PLR and mortality. Neutrophils are essential components of the innate immune system involved in counteracting infections and mediating inflammatory activity. The specific roles that neutrophils play in cancer, however, remain somewhat controversial, potentially owing to their plasticity and the effects of the tumor microenvironment. Both neutrophils and platelets ultimately interact with the tumor microenvironment, influencing immune responses and promoting immune evasion and tumor progression [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. These neutrophils and platelets release cytokines and chemokines, such as TGF-&#x003b2;, VEGF, IL-6, and IL-8 [<xref ref-type="bibr" rid="CR19">19</xref>]. Reductions in lymphocyte counts also tend to be indicative of the impairment of cellular immunity and the corresponding disruption of the immunological landscape. Moreover, neutrophils can release inflammatory mediators that suppress T-cell functions and alter tumor angiogenesis [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Coffelt et al. proposed that targeting a novel immune axis consisting of &#x003b3;&#x003b4; T cells, IL-17, and neutrophils may contribute to a greater risk of metastasis [<xref ref-type="bibr" rid="CR23">23</xref>]. These complex interactions may clarify how these indices are related to tumor progression and immune escape.</p><p id="Par32">Older patients with cancer show a high degree of heterogeneity due to the presence of various comorbidities and differences in the manifestation of aging-related changes [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Personalized treatment strategies should be employed to gauge both the toxicity-related risks and survival prospects of older cancer patients undergoing treatment [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. Sarcopenia, which is associated with both the NLR and PLR [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], can contribute to a heightened inflammatory state, further impacting these ratios [<xref ref-type="bibr" rid="CR30">30</xref>]. This concurrent inflammation can also exacerbate muscle loss, initiating a vicious cycle that negatively affects physical function and treatment outcomes [<xref ref-type="bibr" rid="CR31">31</xref>]. Therefore, monitoring the NLR and PLR can be useful in assessing the health status of cancer patients and gauging the progression of sarcopenia [<xref ref-type="bibr" rid="CR6">6</xref>]. Notably, the NLR is not only a sarcopenia index but also forms part of the Royal Marsden Hospital (RMH) score [<xref ref-type="bibr" rid="CR32">32</xref>]. Furthermore, the metabolic indicators in the RMH score, such as serum albumin, are closely related to sarcopenia, as sarcopenia itself is a syndrome associated with metabolic dysregulation and malnutrition. Therefore, both the NLR and PLR may influence cancer prognosis not only through inflammatory pathways but also <italic>via</italic> metabolic interactions with sarcopenia, further impacting patient survival. The findings of this study provide new insights into the multifaceted roles of the NLR and PLR in cancer prognosis. Future research could explore the relationship between sarcopenia and the RMH score, such as whether patients with sarcopenia are more likely to have higher RMH scores and whether this association is independent of other known prognostic factors.</p><p id="Par33">This study has several limitations. First, the single-center and retrospective design, along with the limited sample size, may have contributed to potential selection bias. Furthermore, several indicators were lacking from the analysis, such as systemic inflammation and Eastern Cooperative Oncology Group scale scores which could not be compensated for due to the retrospective analysis. Second, the study cohort was restricted to individuals of Chinese ethnicity, limiting the generalizability of the results. Third, as we were unable to obtain chest or lumbar spine CT/MRI scans for further analysis. Further exploration in this population should be conducted in future research. Fourth, since analysis of CT images was not possible in this study, the albumin-myosteatosis gauge (AMG) score could not be calculated. The AMG score is typically based on imaging features and reflects the metabolic activity of tumors. Future research could combine imaging indicators (such as AMG) with blood biomarkers (such as NLR and PLR) to more comprehensively evaluate the prognosis of lung cancer patients. Fifth, due to the limited sample size in our study, the relationship between sarcopenia indices (such as NLR and PLR) and survival could not be analyzed further by stratifying patients according to cancer stage. However, this aspect could be explored in larger population-based studies. Sixth, we selected lung cancer patients diagnosed between 2010 and 2017 for analysis. We acknowledge that the widespread use of immunotherapy in recent years may alter the inflammatory status and prognostic patterns of patients, thereby potentially affecting the predictive value of the sarcopenia indices. Future studies are needed to further verify our findings in patient populations that include those receiving immunotherapy.</p></sec><sec id="Sec5"><title>Conclusion</title><p id="Par34">Both the NLR and PLR, which can be calculated based on routinely gathered laboratory data, can predict an increased mortality risk among older female lung cancer patients starting chemotherapeutic treatment. The findings highlight the potential role of these indices as accessible and valuable tools for risk assessment before chemotherapy in this population.</p></sec><sec id="Sec6" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12877_2025_5951_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Shuyue Luo and Xiaoyan Chen contributed equally to this study and should be considered co-first authors of this paper.</p></fn><fn><p>Ming Yang and Qiukui Hao contributed equally to this study and should be considered co-coresponding authors of this paper.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We thank all personnel for their contribution in the study.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Xiaoyan Chen and Shuyue Luo wrote the main manuscript text and Li sha Hou prepared figures <xref rid="Fig1" ref-type="fig">1</xref>;. Xiaoyan Chen and Qiukui Hao perpared the tables. Qiukui Hao and Ming Yang reviewed the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was funded by Zigong City Key Science and Technology Plan Project (Zigong Brain Science Research Institute Collaborative Innovation Category) (Project No. 2023-NKY-01-03, 2024-NKY-01-03), Zigong Psychiatric Research Center scientific research project (Project No. 2022ZD01, 2022ZD03). We appreciate all participants and legal proxies for their great contributions. The sponsors played no role in the design, methods, data collection, analysis and preparation of this paper.</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>If the request is reasonable, the original data can be obtained. Please contact the corresponding author, Professor Hao Qiukui, at haoqiukui@gmail.com.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par35">This study was conducted in accordance with the Declaration of Helsinki and the ethical approval was obtained from the Research Ethics Committee of West China Hospital, Sichuan University (No. 2018&#x02013;94). Given the anonymized and retrospective nature of this study, the requirement for patient consent was waived. All methods comply with relevant guidelines and regulations.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par36">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par37">The authors declare no competing interests.</p></notes></notes><glossary><title>Abbreviations</title><def-list><def-item><term>NLR</term><def><p id="Par38">Neutrophil-to-lymphocyte ratio</p></def></def-item><def-item><term>PLR</term><def><p id="Par39">Platelet-to-lymphocyte ratio</p></def></def-item><def-item><term>OS</term><def><p id="Par40">Overall survival</p></def></def-item><def-item><term>BMI</term><def><p id="Par41">Body mass index</p></def></def-item><def-item><term>OR</term><def><p id="Par42">Odds ratio</p></def></def-item><def-item><term>CI</term><def><p id="Par43">Confidence interval</p></def></def-item><def-item><term>RMH</term><def><p id="Par44">Royal marsden hospital</p></def></def-item><def-item><term>AMG</term><def><p id="Par45">Albumin-myosteatosis gauge</p></def></def-item></def-list></glossary><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Siegel</surname><given-names>RL</given-names></name><name><surname>Giaquinto</surname><given-names>AN</given-names></name><name><surname>Jemal</surname><given-names>A</given-names></name></person-group><article-title>Cancer statistics, 2024</article-title><source>CA Cancer J Clin</source><year>2024</year><volume>74</volume><issue>1</issue><fpage>12</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.3322/caac.21820</pub-id><pub-id pub-id-type="pmid">38230766</pub-id>
</element-citation><mixed-citation id="mc-CR1" publication-type="journal">Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12&#x02013;49.<pub-id pub-id-type="pmid">38230766</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Riely</surname><given-names>GJ</given-names></name><etal/></person-group><article-title>Non-Small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology</article-title><source>J Natl Compr Canc Netw</source><year>2024</year><volume>22</volume><issue>4</issue><fpage>249</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.6004/jnccn.2204.0023</pub-id><pub-id pub-id-type="pmid">38754467</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Riely GJ, et al. Non-Small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22(4):249&#x02013;74.<pub-id pub-id-type="pmid">38754467</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Cruz-Jentoft</surname><given-names>AJ</given-names></name><name><surname>Sayer</surname><given-names>AA</given-names></name></person-group><source>Sarcopenia Lancet</source><year>2019</year><volume>393</volume><issue>10191</issue><fpage>2636</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(19)31138-9</pub-id><pub-id pub-id-type="pmid">31171417</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Cruz-Jentoft AJ, Sayer AA. Sarcopenia Lancet. 2019;393(10191):2636&#x02013;46.<pub-id pub-id-type="pmid">31171417</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Yeung</surname><given-names>SSY</given-names></name><etal/></person-group><article-title>Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis</article-title><source>J Cachexia Sarcopenia Muscle</source><year>2019</year><volume>10</volume><issue>3</issue><fpage>485</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1002/jcsm.12411</pub-id><pub-id pub-id-type="pmid">30993881</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Yeung SSY, et al. Sarcopenia and its association with falls and fractures in older adults: A systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2019;10(3):485&#x02013;500.<pub-id pub-id-type="pmid">30993881</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>H</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name></person-group><article-title>The association between sarcopenia and functional disability in older adults</article-title><source>J Nutr Health Aging</source><year>2024</year><volume>28</volume><issue>1</issue><fpage>100016</fpage><pub-id pub-id-type="doi">10.1016/j.jnha.2023.100016</pub-id><pub-id pub-id-type="pmid">38267154</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Zhou H, Ding X, Luo M. The association between sarcopenia and functional disability in older adults. J Nutr Health Aging. 2024;28(1):100016.<pub-id pub-id-type="pmid">38267154</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="other">Zhang Y et al. Sarcopenia is a prognostic factor of adverse effects and mortality in patients with tumour: A systematic review and Meta-Analysis. J Cachexia Sarcopenia Muscle, 2024.</mixed-citation></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>LK</given-names></name><etal/></person-group><article-title>Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment</article-title><source>J Am Med Dir Assoc</source><year>2020</year><volume>21</volume><issue>3</issue><fpage>300</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.jamda.2019.12.012</pub-id><pub-id pub-id-type="pmid">32033882</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Chen LK, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300&#x02013;7. e2.<pub-id pub-id-type="pmid">32033882</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Ramaswamy</surname><given-names>R</given-names></name></person-group><article-title>In frail older adults with sarcopenia, a multicomponent intervention vs. education reduced mobility disability at 26 mo</article-title><source>Ann Intern Med</source><year>2022</year><volume>175</volume><issue>9</issue><fpage>Jc103</fpage><pub-id pub-id-type="doi">10.7326/J22-0062</pub-id><pub-id pub-id-type="pmid">36063547</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Ramaswamy R. In frail older adults with sarcopenia, a multicomponent intervention vs. education reduced mobility disability at 26 mo. Ann Intern Med. 2022;175(9):Jc103.<pub-id pub-id-type="pmid">36063547</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Yin</surname><given-names>M</given-names></name><etal/></person-group><article-title>Diagnostic performance of clinical laboratory indicators with sarcopenia: results from the West China health and aging trend study</article-title><source>Front Endocrinol (Lausanne)</source><year>2021</year><volume>12</volume><fpage>785045</fpage><pub-id pub-id-type="doi">10.3389/fendo.2021.785045</pub-id><pub-id pub-id-type="pmid">34956096</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Yin M, et al. Diagnostic performance of clinical laboratory indicators with sarcopenia: results from the West China health and aging trend study. Front Endocrinol (Lausanne). 2021;12:785045.<pub-id pub-id-type="pmid">34956096</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Q</given-names></name><etal/></person-group><article-title>High Neutrophil-to-Lymphocyte ratio and Platelet-to-Lymphocyte ratio are associated with sarcopenia risk in hospitalized renal cell carcinoma patients</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><fpage>736640</fpage><pub-id pub-id-type="doi">10.3389/fonc.2021.736640</pub-id><pub-id pub-id-type="pmid">34760698</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Hu Q, et al. High Neutrophil-to-Lymphocyte ratio and Platelet-to-Lymphocyte ratio are associated with sarcopenia risk in hospitalized renal cell carcinoma patients. Front Oncol. 2021;11:736640.<pub-id pub-id-type="pmid">34760698</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Pizzimenti</surname><given-names>M</given-names></name><etal/></person-group><article-title>Usefulness of Platelet-to-Lymphocyte ratio as a marker of sarcopenia for critical limb threatening ischemia</article-title><source>Ann Vasc Surg</source><year>2021</year><volume>72</volume><fpage>72</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.avsg.2020.05.027</pub-id><pub-id pub-id-type="pmid">32479878</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Pizzimenti M, et al. Usefulness of Platelet-to-Lymphocyte ratio as a marker of sarcopenia for critical limb threatening ischemia. Ann Vasc Surg. 2021;72:72&#x02013;8.<pub-id pub-id-type="pmid">32479878</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>Y</given-names></name><etal/></person-group><article-title>High serum AST/ALT ratio and low serum INS*PA product are risk factors and can diagnose sarcopenia in Middle-Aged and older adults</article-title><source>Front Endocrinol (Lausanne)</source><year>2022</year><volume>13</volume><fpage>843610</fpage><pub-id pub-id-type="doi">10.3389/fendo.2022.843610</pub-id><pub-id pub-id-type="pmid">35370985</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">He Y, et al. High serum AST/ALT ratio and low serum INS*PA product are risk factors and can diagnose sarcopenia in Middle-Aged and older adults. Front Endocrinol (Lausanne). 2022;13:843610.<pub-id pub-id-type="pmid">35370985</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Sel&#x000e7;uk</surname><given-names>N</given-names></name><etal/></person-group><article-title>Sarcopenia is a risk factor for major adverse cardiac events after surgical revascularization for critical limb ischemia</article-title><source>Vascular</source><year>2023</year><volume>31</volume><issue>1</issue><fpage>64</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1177/17085381211059383</pub-id><pub-id pub-id-type="pmid">34974778</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Sel&#x000e7;uk N, et al. Sarcopenia is a risk factor for major adverse cardiac events after surgical revascularization for critical limb ischemia. Vascular. 2023;31(1):64&#x02013;71.<pub-id pub-id-type="pmid">34974778</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Petrova</surname><given-names>MP</given-names></name><etal/></person-group><article-title>Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer</article-title><source>Clin Exp Immunol</source><year>2020</year><volume>202</volume><issue>3</issue><fpage>353</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1111/cei.13505</pub-id><pub-id pub-id-type="pmid">32757277</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Petrova MP, et al. Sarcopenia and high NLR are associated with the development of hyperprogressive disease after second-line pembrolizumab in patients with non-small-cell lung cancer. Clin Exp Immunol. 2020;202(3):353&#x02013;62.<pub-id pub-id-type="pmid">32757277</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Go</surname><given-names>SI</given-names></name><etal/></person-group><article-title>Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer</article-title><source>Support Care Cancer</source><year>2016</year><volume>24</volume><issue>5</issue><fpage>2075</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1007/s00520-015-2997-x</pub-id><pub-id pub-id-type="pmid">26546456</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Go SI, et al. Sarcopenia and inflammation are independent predictors of survival in male patients newly diagnosed with small cell lung cancer. Support Care Cancer. 2016;24(5):2075&#x02013;84.<pub-id pub-id-type="pmid">26546456</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>MD</given-names></name></person-group><article-title>Sex differences in immune responses in COVID-19</article-title><source>Nat Rev Immunol</source><year>2020</year><volume>20</volume><issue>8</issue><fpage>461</fpage><pub-id pub-id-type="doi">10.1038/s41577-020-0378-2</pub-id><pub-id pub-id-type="pmid">32572247</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Park MD. Sex differences in immune responses in COVID-19. Nat Rev Immunol. 2020;20(8):461.<pub-id pub-id-type="pmid">32572247</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Giefing-Kr&#x000f6;ll</surname><given-names>C</given-names></name><etal/></person-group><article-title>How sex and age affect immune responses, susceptibility to infections, and response to vaccination</article-title><source>Aging Cell</source><year>2015</year><volume>14</volume><issue>3</issue><fpage>309</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/acel.12326</pub-id><pub-id pub-id-type="pmid">25720438</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Giefing-Kr&#x000f6;ll C, et al. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell. 2015;14(3):309&#x02013;21.<pub-id pub-id-type="pmid">25720438</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Rakshith</surname><given-names>HT</given-names></name></person-group><article-title>Raghavendra Naveen N. Sex differences in drug effects and/or toxicity in oncology</article-title><source>Curr Res Pharmacol Drug Discov</source><year>2023</year><volume>4</volume><fpage>100152</fpage><pub-id pub-id-type="doi">10.1016/j.crphar.2022.100152</pub-id><pub-id pub-id-type="pmid">36714036</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Rakshith HT. Raghavendra Naveen N. Sex differences in drug effects and/or toxicity in oncology. Curr Res Pharmacol Drug Discov. 2023;4:100152.<pub-id pub-id-type="pmid">36714036</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Treffers</surname><given-names>LW</given-names></name><etal/></person-group><article-title>Neutrophils in cancer</article-title><source>Immunol Rev</source><year>2016</year><volume>273</volume><issue>1</issue><fpage>312</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1111/imr.12444</pub-id><pub-id pub-id-type="pmid">27558343</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Treffers LW, et al. Neutrophils in cancer. Immunol Rev. 2016;273(1):312&#x02013;28.<pub-id pub-id-type="pmid">27558343</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Tuerhong</surname><given-names>N</given-names></name><etal/></person-group><article-title>Interactions between platelets and the cancer immune microenvironment</article-title><source>Crit Rev Oncol Hematol</source><year>2024</year><volume>199</volume><fpage>104380</fpage><pub-id pub-id-type="doi">10.1016/j.critrevonc.2024.104380</pub-id><pub-id pub-id-type="pmid">38718939</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Tuerhong N, et al. Interactions between platelets and the cancer immune microenvironment. Crit Rev Oncol Hematol. 2024;199:104380.<pub-id pub-id-type="pmid">38718939</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Sabbione</surname><given-names>F</given-names></name><etal/></person-group><article-title>Neutrophils suppress &#x00393;&#x003b4; T-cell function</article-title><source>Eur J Immunol</source><year>2014</year><volume>44</volume><issue>3</issue><fpage>819</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1002/eji.201343664</pub-id><pub-id pub-id-type="pmid">24271816</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Sabbione F, et al. Neutrophils suppress &#x00393;&#x003b4; T-cell function. Eur J Immunol. 2014;44(3):819&#x02013;30.<pub-id pub-id-type="pmid">24271816</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Fridlender</surname><given-names>ZG</given-names></name><name><surname>Albelda</surname><given-names>SM</given-names></name><name><surname>Granot</surname><given-names>Z</given-names></name></person-group><article-title>Promoting metastasis: neutrophils and T cells join forces</article-title><source>Cell Res</source><year>2015</year><volume>25</volume><issue>7</issue><fpage>765</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1038/cr.2015.62</pub-id><pub-id pub-id-type="pmid">26138787</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Fridlender ZG, Albelda SM, Granot Z. Promoting metastasis: neutrophils and T cells join forces. Cell Res. 2015;25(7):765&#x02013;6.<pub-id pub-id-type="pmid">26138787</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Coffelt</surname><given-names>SB</given-names></name><etal/></person-group><article-title>IL-17-producing &#x00393;&#x003b4; T cells and neutrophils conspire to promote breast cancer metastasis</article-title><source>Nature</source><year>2015</year><volume>522</volume><issue>7556</issue><fpage>345</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1038/nature14282</pub-id><pub-id pub-id-type="pmid">25822788</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Coffelt SB, et al. IL-17-producing &#x00393;&#x003b4; T cells and neutrophils conspire to promote breast cancer metastasis. Nature. 2015;522(7556):345&#x02013;8.<pub-id pub-id-type="pmid">25822788</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Petermann-Rocha</surname><given-names>F</given-names></name><etal/></person-group><article-title>Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis</article-title><source>J Cachexia Sarcopenia Muscle</source><year>2022</year><volume>13</volume><issue>1</issue><fpage>86</fpage><lpage>99</lpage><pub-id pub-id-type="doi">10.1002/jcsm.12783</pub-id><pub-id pub-id-type="pmid">34816624</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Petermann-Rocha F, et al. Global prevalence of sarcopenia and severe sarcopenia: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2022;13(1):86&#x02013;99.<pub-id pub-id-type="pmid">34816624</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Couderc AL et al. Pre-Therapeutic sarcopenia among Cancer patients: an Up-to-Date Meta-Analysis of prevalence and predictive value during Cancer treatment. Nutrients, 2023. 15(5).</mixed-citation></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Pallis</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Management of elderly patients with NSCLC; updated expert&#x02019;s opinion paper: EORTC elderly task force, lung Cancer group and international society for geriatric oncology</article-title><source>Ann Oncol</source><year>2014</year><volume>25</volume><issue>7</issue><fpage>1270</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1093/annonc/mdu022</pub-id><pub-id pub-id-type="pmid">24638905</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Pallis AG, et al. Management of elderly patients with NSCLC; updated expert&#x02019;s opinion paper: EORTC elderly task force, lung Cancer group and international society for geriatric oncology. Ann Oncol. 2014;25(7):1270&#x02013;83.<pub-id pub-id-type="pmid">24638905</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Clough-Gorr</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up</article-title><source>J Clin Oncol</source><year>2010</year><volume>28</volume><issue>3</issue><fpage>380</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.23.5440</pub-id><pub-id pub-id-type="pmid">20008637</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Clough-Gorr KM, et al. Older breast cancer survivors: geriatric assessment domains are associated with poor tolerance of treatment adverse effects and predict mortality over 7 years of follow-up. J Clin Oncol. 2010;28(3):380&#x02013;6.<pub-id pub-id-type="pmid">20008637</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Prognostic value of systemic inflammation, nutritional status and sarcopenia in patients with amyotrophic lateral sclerosis</article-title><source>J Cachexia Sarcopenia Muscle</source><year>2024</year><volume>15</volume><issue>6</issue><fpage>2743</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.1002/jcsm.13618</pub-id><pub-id pub-id-type="pmid">39449162</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Zhu Y, et al. Prognostic value of systemic inflammation, nutritional status and sarcopenia in patients with amyotrophic lateral sclerosis. J Cachexia Sarcopenia Muscle. 2024;15(6):2743&#x02013;55.<pub-id pub-id-type="pmid">39449162</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>K</given-names></name><etal/></person-group><article-title>Sarcopenia accompanied by systemic inflammation can predict clinical outcomes in patients with head and neck cancer undergoing curative therapy</article-title><source>Front Oncol</source><year>2024</year><volume>14</volume><fpage>1378762</fpage><pub-id pub-id-type="doi">10.3389/fonc.2024.1378762</pub-id><pub-id pub-id-type="pmid">38549928</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">Kasahara K, et al. Sarcopenia accompanied by systemic inflammation can predict clinical outcomes in patients with head and neck cancer undergoing curative therapy. Front Oncol. 2024;14:1378762.<pub-id pub-id-type="pmid">38549928</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Ucgul</surname><given-names>E</given-names></name><etal/></person-group><article-title>Factors influencing immunotherapy outcomes in cancer: sarcopenia and systemic inflammation</article-title><source>Cancer Control</source><year>2024</year><volume>31</volume><fpage>10732748241302248</fpage><pub-id pub-id-type="doi">10.1177/10732748241302248</pub-id><pub-id pub-id-type="pmid">39547932</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ucgul E, et al. Factors influencing immunotherapy outcomes in cancer: sarcopenia and systemic inflammation. Cancer Control. 2024;31:10732748241302248.<pub-id pub-id-type="pmid">39547932</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="other">Luo X et al. Molecular mechanisms and potential interventions during Aging-associated sarcopenia. Mech Ageing Dev, 2024: p. 112020.</mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Sahin TK et al. Prognostic significance of the Royal marsden hospital (RMH) score in patients with cancer: A systematic review and Meta-Analysis. Cancers (Basel), 2024. 16(10).</mixed-citation></ref></ref-list></back></article>